🇺🇸 Follitropin beta injection in United States

4 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Window: 23 April 2025 – 23 April 2026
Total reports: 4

Most-reported reactions

Abdominal Pain — 1 report (25%)
Ascites — 1 report (25%)
Ovarian Hyperstimulation Syndrome — 1 report (25%)
Pleural Effusion — 1 report (25%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Follitropin beta injection approved in United States?

Follitropin beta injection does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Follitropin beta injection in United States?

Organon and Co is the originator. The local marketing authorisation holder may differ — check the official source linked above.